ACA
AUPH icon

Avoro Capital Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Avoro Capital Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,670,000
Closed -$27.1M – 49
2020
Q2 		$27.1M Sell
1,670,000
-55,000
-3% -$881K 0.54% 31
2020
Q1 		$25M Buy
+1,725,000
New +$30.4M 0.84% 26

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Avoro Capital Advisors's AUPH Position: Q3 2020 in Review

Avoro Capital Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2020, closing a stake of 1,670,000 shares — an estimated $27.1M sold.

Avoro Capital Advisors first reported a position in AUPH in Q1 2020 and held it in 2 quarters. The position peaked at $27.1M in Q2 2020. 145 funds tracked by Wall St. Rank hold AUPH as of Q3 2020.

  • Avoro Capital Advisors reported no remaining Aurinia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Avoro Capital Advisors sold 1,670,000 Aurinia Pharmaceuticals shares in Q3 2020, an estimated $27.1M.
  • Avoro Capital Advisors first reported a position in Aurinia Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Avoro Capital Advisors's Aurinia Pharmaceuticals position peaked at $27.1M in Q2 2020.
  • 145 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2020.

Based on Avoro Capital Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.